Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
.37 going out of business sale
ALLR .39 going out of business sale
BOLD WLDS JAN SGLY GROM
EPOW almost $1 + 70% .. unrise New Energy’s Lithium-Ion Battery Patent Granted Key Funding in Guizhou Province
Source: GlobeNewswire Inc.
Sunrise New Energy Co., Ltd. (“Sunrise New Energy”, the “Company”, “we” or “our”) (NASDAQ: EPOW), today announced that its subsidiary, Sunrise (Guizhou) New Energy Co., Ltd., has been selected for the "2024 Guizhou Provincial Key Projects for Promoting the Utilization of Intellectual Property" funding list. This recognition was released by the Guizhou Provincial Market Supervision Administration (Intellectual Property Office) on June 17th, marking a significant milestone for the Company.
The selected project is the "Preparation Method of Lithium-Ion Battery Anode Material" (Patent No. ZL202210400775.2). This patent solves the critical and common technical issue of balancing power performance and initial efficiency. It enhances the initial efficiency and power performance of graphite composite materials, providing an excellent solution for the next generation of high-energy-density fast-charging batteries, which has vast market potential.
The Company has leveraged this patent to manufacture and widely distribute products over the past two years. Sunrise New Energy’s products are used in conjunction with well-known battery manufacturers such as Contemporary Amperex Technology Co., Ltd. (CATL) and BYD Company Limited (BYD). Due to its stable performance, the patented product holds a significant competitive advantage in the market and has received unanimous praise for its quality. Since the sales of the patented product began in 2022, despite the short period, the product has rapidly gained market traction. To date, the cumulative sales revenue has reached approximately $100 million.
.97 almost $1 afterhours
NXL closed at 1.69 .hit 2.50 afterhours at 2.30s now and coming back down ..GOVX hanging in and ICU continues run
NXL up up and away $2.50s selling some $1.80s
NXL $10 wouldn’t be surprised unmet need and low floater
NXL 2.39 + 119% .. Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
Source: GlobeNewswire Inc.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation (DIFS®) medical device for the treatment of Alzheimer’s and other dementia-related brain diseases. The newly issued patent entitled, “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method for Alzheimer’s and Dementia,” relates to the Company’s Gen-2 and Gen-3 brain stimulation medical device that administers a proprietary frequency based waveform that is designed to effectively treat patients in a pain free and undetectable manner.
Mark White, CEO of Nexalin Technology, stated, “The award of this patent marks another major milestone for the Company, as we expand our intellectual property to include the treatment of Alzheimer’s and dementia. According to Grandview Research, the global dementia treatment market is estimated to be in excess of $18 billion and is projected to reach over $28 billion by 2030. This growth is driven by the increasing prevalence of various forms of dementia. According to the World Health Organization, more than 55 million people currently live with dementia and nearly 10 million new cases are diagnosed every year. The market is further bolstered by significant investments in research and development. According to the Alzheimer’s Association, annual funding for Alzheimer’s and dementia research by the federal government is estimated to be in excess of $3 billion annually, which underscores the critical need for innovative treatments like Nexalin's neurostimulation device. Our growing body of published clinical studies supports the clinical benefits of our device for the treatment of a variety of neurological diseases associated with deep brain structures, ranging from treatment-resistant depression to migraines, anxiety, insomnia, addiction and PTSD. Similarly, we believe that our DIFS® technology holds the potential to revolutionize the standard of care for additional mental health disorders such as Alzheimer’s and dementia.”
The Gen-2 and Gen-3 medical device reflects the state-of-the-art development of Nexalin’s Deep Intracranial Frequency Stimulation (DIFS®) technology, and a significant advancement to the predecessor Gen-1 system. The Company’s new neuro-technology marks a digital breakthrough in electrical waveforms to provide a deep undetectable non-invasive brain stimulation technique that is designed to be safe, risk-free and highly effective. The Gen-2 and Gen-3 stimulation technique relies on the placement of strategically positioned electrodes on the patient’s cranium, and provides deep stimulation to regions of the brain associated with mental health conditions.
Nice ICU 6.50+ 23%
ICU 6.20 +’18% AREB .93 trying for $1 might have some sizzle left
ICU $3s to 5.75+ 8% past few days low floater after RS medical device kidney
SRPT $169 +35% Elevidys is among the most expensive treatments in the world with a list price of $3.2 million.
Sales of the therapy came in at $200.4 million in 2023 and are expected to rise to $1.07 billion this year, as per LSEG data.
DMD is an inherited progressive muscle-wasting disorder that affects an estimated one-in-3,500 male births worldwide, according to the U.S.-based National Organization for Rare Disorders.
Elevidys' could now be given to about 13,000 patients, or nearly 90% of U.S. patients, said BMO Capital analyst Kostas Biliouris.
The decision also follows concerns around an "uphill battle" to secure traditional approval after the therapy failed to meet the main goal in a key confirmatory late-stage trial.
A top official of the agency, Peter Marks, pushed for the "no strings attached" label for Elevidys overruling recommendations, RBC markets analyst Luca Issi said. FDA staff had recommended declining the expansion, citing a lack of benefit to certain patients, documents show.
The global treatment market for DMD - including gene therapies and other drugs - is expected to grow to $11.47 billion by 2034, according to ResearchandMarkets.com.
LICY 5.23 + 12% 15m float see if it pushes above 5.70 resistance . Lithium graphite recycling play
AREB .89 start cashing casino chips in .80s still a small chance for $1 -1.15 resistance
YOSH + 16% 4.34 500k floater have some California sushi with that AREB Connecticut beer
AREB .79 + 150% beer is on me lol
SRFM .55 + 72% surfing between .40s and .60s
SRFM surfing between .40s and .60s
Late to the SPEC party..lol
Time for a $SPECtacle .55 +’60%
PBM and ENSC aftermarket boom
KTRA .27 + 28% moon play not bad with .32 and .50 resistances too ponder and then the moon to $3. Cancer vaccine and merger. Congresswoman involved in play.
SMFL $3.60s +’11% 200k float and Whole Foods help it longer term
Witches working this round for SOXS wasn stopped out too early (for kettle pot and broom party) week ago
GOVX $2 warrants up 2,500% .09 to .60 this premarket more room to run here with …Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study. The government will also provide around $343M for a clinical research organization to conduct the clinical trial.
NNVC AONC NNE KA ICU DECA APLD HOLO
June’s Quad Witching Options Expiration – A Volatility Haven ¦ Jeff Hirsch
The second Quadruple Witching Week of the year brings on some volatile trading with losses frequently exceeding gains. NASDAQ has the weakest record on the first trading day of the week, down 23 times in 42 years. Quad-Witching Friday is usually better, S&P 500 has been up 12 of the last 21 years, but down 6 of the last 8.
https://time-price-research-astrofin.blogspot.com/2024/06/junes-quad-witching-options-expiration.html?m=1
HOLO 1.10 + 166 look at 1.38 resistance first then 1.65-1.75 then 1.98. Resistances pretty weak should break quickly when ready
ALUR 3.55 hod 2.80 nice eye enjoy the gains as it stands 3.70- 3.80s resistance at play
ALUR 2.28 + 110% start cashing out casino chips
SLNH 6.36 +31% great June for company…June 5th CEO’s Letter to Shareholders – CEO John Belizaire shared the Company’s 2024 strategy and roadmap for profitability.
2024 Earnings Power Presentation – The Company published its updated annual Earnings Power Presentation that includes Project Dorothy 2.
Project Kati PPA – Secured 166 MW PPA with EDF Renewables and Masdar for Project Kati in Texas. Unlocks significant Hosting potential.
Financing Secured for Project Dorothy 2 - Spring Lane Capital has agreed to lead the financing round for Project Dorothy 2 with a commitment of up to $30 million. Learn more here.
Strategic Collaboration for AI Business – We launched Soluna Cloud, our new subsidiary focused on sustainable, scalable AI Cloud and hosting services in collaboration with a Leading High-Performance Computing Company
Quick Takes Video Series - CEO John Belizaire discusses “Convergence and the Power of AI”, and Soluna’s under-rated resilience. Watch here.
AMA - The Company published responses to investor questions in its monthly AMA for April. View the responses here.
Key Project Updates:
Project Dorothy 1A (25 MW, Hosting) / Project Dorothy 1B (25 MW, Prop-Mining):
Preparations for the onset of the Four Coincident Peak Program (4CP) to begin in June through September are underway. With our participation in the program, our MaestroOS software will dynamically maintain site operations compliance with ERCOT demand thresholds through the summer months to support local community needs.
Actual power consumption and uptime % continued to remain steady for the month of May and in line with month-over-month performance.
Project Dorothy 2 (50 MW):
Project schedule in the process of being finalized with the substation interconnection targeted for late fall preceding energization of the initial 16 of 48 MW aimed for by the end of 2024.
Power partner’s approval process is nearing completion.
Spring Lane’s definitive documentation is underway.
Project Sophie (25 MW, Bitcoin Hosting with Profit Share, AI Hosting):
The team responded exceptionally well, mitigating the impacts of recent tornadoes in the Kentucky region. Despite widespread outages, their efforts resulted in minimal downtime at the site.
Infrastructure optimization efforts are ongoing to prepare for the summer heat.
Infrastructure upgrades are underway to support the growth of AI Hosted Clients.
Project Kati (166 MW):
PPA agreements signed with EDF Renewables and Masdar.
Retail Electrical Provider agreements executed with Tenaska.
ERCOT planning continues to progress with final edits made on one key study.
Negotiations continue with landowners for the site land leases.
IBRX $7.31 + 17% 09:45 AM EDT,06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.
The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.
09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.
The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.
ALUR 1.20 to 2 at 1.48 + 40% Jun. 20, 2024--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program. Vital signs and physical activity were tracked in real-time with the Allurion App, Connected Scale, and Health Tracker, and follow-up was provided through the AI-powered Allurion Virtual Care Suite.
In the study, 571 patients across three obesity centers treated with the Allurion Program reduced their weight on average by 13.9kg from 97.9kg to 84.0kg in just four months. Over that same period, lean mass—which includes muscle mass—increased by 2.8kg on average from 49.8kg to 52.6kg.
Higher activity patients, walking more than 8,000 daily steps on average, achieved higher weight loss (15.6kg on average, from 97.7kg to 82.1kg) and gained more lean mass (increased by 2.8kg on average from 50.9kg to 53.7kg) than their lower activity counterparts who achieved a weight loss of 13.6kg on average, from 98.2kg to 84.6kg, and whose lean mass increased by 1.8kg on average, from 49.5 to 51.3kg.
All patients experienced significant reductions in body fat percentage, decreasing from 32.7% to 27.9% in just 4 months.
Previous studies evaluating body composition changes in patients treated with GLP-1s have demonstrated that lean body mass losses are common, ranging from 3-11% lean mass reductions after around a year of treatment. Importantly, these studies did not incorporate any real-time monitoring of body composition or personalized approaches to promote lean mass preservation or muscle mass gain.1,2
“Historically, weight loss has come at the expense of lean muscle mass, the maintenance of which is critical to overall health. These results demonstrate just the opposite, providing evidence that it is possible to lose significant amounts of weight while maintaining, and even increasing, lean body mass,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “We believe that this data underscores the impact of real-time monitoring of body composition and personalized recommendations through our AI-powered Virtual Care Suite. In fact, we believe that using Allurion’s AI platform with other modalities—including GLP-1s, where muscle mass loss is a significant risk—may be a promising path forward.”
Sources: 1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. 2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
ZAPP 3.84 start cashing in casino chips
ZAPP 3.22 + 136%
ZAPPed again $2.91HOLO 1.20 cashing out on the way up .hold 20% longer term .cost average .95 as may just be a temp run again
HOLO 1.08 those .80s paying off
Why not ? look at that government funding $400million GOVX will be in $4s when they let it go